| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Tozadenant (formerly RO-4494351; SYN-115) is an orally bioavailable, selective adenosine A2A receptor antagonist with potential usefulness in the treatment of Parkinson disease (PD). It inhibits A2A receptor with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. It enhances motor function in Parkinson's disease animal models. Antagonists of the adenosine A(2a) receptor lessen the severity of symptoms in animal models and people with Parkinson's disease (PD). The theory that A(2a) antagonists provide this benefit by lowering the basal ganglia indirect pathway's inhibitory output is supported by research on rodents.
| Targets |
Rhesus A2A ( Ki = 6 nM ); Human A2A ( Ki = 11.5 nM )
|
|---|---|
| ln Vivo |
In line with the distribution of A2A receptors in the brain, 18F-MNI-444 exhibits regional uptake. Tozadenant (1.5, 10.5 mg/kg) and preladenant’s dose-dependent blocking show selectivity[1].
|
| References |
| Molecular Formula |
C19H26N4O4S
|
|---|---|
| Molecular Weight |
406.4991
|
| Exact Mass |
406.17
|
| Elemental Analysis |
C, 56.14; H, 6.45; N, 13.78; O, 15.74; S, 7.89
|
| CAS # |
870070-55-6
|
| Appearance |
Solid powder
|
| SMILES |
CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O
|
| InChi Key |
XNBRWUQWSKXMPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
|
| Chemical Name |
4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide
|
| Synonyms |
RO 4494351; SYN 115; RO-4494351; SYN115; RO4494351; RO4494351-002; SYN-115; RO4494351-000
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~123.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4600 mL | 12.3001 mL | 24.6002 mL | |
| 5 mM | 0.4920 mL | 2.4600 mL | 4.9200 mL | |
| 10 mM | 0.2460 mL | 1.2300 mL | 2.4600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02240290 | Completed | Drug: tozadenant tablet Drug: C14-tozadenant capsule |
N/A, as Healthy Volunteers | Biotie Therapies Inc. | September 2013 | Phase 1 |
| NCT00605553 | Completed | Drug: Placebo Drug: Tozadenant |
Parkinson's Disease | Biotie Therapies Inc. | April 2008 | Phase 2 |
| NCT01283594 | Completed | Drug: Placebo Drug: Levodopa (L-dopa) |
Parkinson's Disease | Biotie Therapies Inc. | March 2011 | Phase 2 Phase 3 |
| NCT00783276 | Completed | Drug: SYN115 Drug: PLACEBO |
Cocaine Dependence | Virginia Commonwealth University | October 2008 | Early Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA